| Followers | 905 |
| Posts | 39732 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Monday, January 22, 2024 10:16:16 AM
TNYA...DON'T YOU DARE...FUC OFF!!!
Recent TNYA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 11:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 11:06:46 PM
- Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC • GlobeNewswire Inc. • 05/15/2026 10:01:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:24:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:11:42 PM
- Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 08:05:00 PM
- Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/16/2026 01:14:44 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 01:11:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 01:00:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2026 08:28:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2026 08:14:26 PM
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 03/09/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:25 PM
- Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 12:15:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 12:13:30 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/18/2026 12:09:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 11:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 11:02:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/03/2026 09:06:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 10:06:08 PM
- Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones • GlobeNewswire Inc. • 01/09/2026 01:30:00 PM
